Abstract Body

The Aβ-misfolding is a promising structure biomarker which could identify AD up to 14 years before clinical conversion ^1,2,3,4. Additional use of the Tau structure biomarker increases the sensitivity and specificity⁵.

Objectives:

The performance as a prognostic plasma biomarker in individuals with subjective cognitive decline (SCD) is shown⁷.

Methods:

Baseline plasma samples of SCD subjects were analyzed using the immuno-infrared-sensor. We used COX proportional hazard models to quantify the Ab-misfolding as prognostic biomarker for future clinical conversion to mild cognitive impairment (MCI) or Alzheimer’s disease (AD). The accuracy was determined by time-dependent ROC-curve-analyses.

Results:

A hazard ratio (HR) of 19 was obtained; T-ROC curve analyses yielded an AUC of 0.94. Using in addition plasma Ab42/40 provides an added value with an AUC of 0.99 six years before clinical conversion^6,7.

Conclusions:

The proposed plasma biomarker panel can precisely predict conversion to clinical MCI and AD in cognitively unimpaired subjects. They allow screening of the aging population for prevention and early intervention in symptom-free stages.

1. Nabers A, et al. J.Biophotonics. 2016;9(3):224-34.

2. Schartner J, et al. ACSMed.Chem.Lett. 2017Jun11;8(7):710-714.

3. Nabers A, et al. EMBO.Mol.Med. 2018May;10(5).

4. Stocker H, et al. Alzheimer&Dement. . 2020;16:283–91.

5. Nabers A, et al. Alzheimer&Dement. 2019;11:257-263.

6. Verberk et al. Ann Neurol. 2018;84:648–58.

7. Stockmann J*,Verberk, I…, Scheltens, P. Teunissen CE, Gerwert K. under review.